Clinicians at the CHRU de Nancy launched a targeted screening campaign for transthyretin amyloidosis, a systemic infiltrative disease known as the chameleon disease.
Unmasking the Chameleon Disease
The condition remains frequently misdiagnosed because its initial clinical manifestations mimic common orthopedic and rheumatological disorders.
Misfolded Proteins Form Insoluble Amyloid Fibrils
Transthyretin amyloidosis, or TTR amyloidosis, is classified as an infiltrative pathology driven by protein misfolding. Under normal physiological conditions, the liver synthesizes transthyretin (TTR), a transport protein that circulates freely in the bloodstream to carry vital substances.
Over time, particularly with aging, the structure of this protein alters. The altered proteins dissociate and assemble into insoluble amyloid fibrils. These fibrils infiltrate multiple organ systems, including peripheral nerve sheaths, joints, ocular tissues, and predominantly the myocardium.
Because the clinical manifestations span multiple medical specialties, practitioners frequently struggle to establish a timely diagnosis. The condition earned its chameleon moniker precisely due to this diverse and insidious presentation.
Orthopedic Warning Signs at Nancy
The diagnostic challenge begins in the early phases, where the disease presents with benign musculoskeletal symptoms. Specialists often treat these initial signs as isolated orthopedic complaints rather than indicators of systemic disease.
Carpal tunnel syndrome often serves as the initial red flag years before cardiac or neurological symptoms manifest. When bilateral carpal tunnel syndrome appears alongside orthopedic anomalies, clinicians at CHRU de Nancy urge heightened vigilance to catch the underlying amyloid deposition before irreversible tissue damage occurs.
Patients with Persistent Symptoms Require Specialized Neurological Evaluation
Patients experiencing persistent, bilateral carpal tunnel syndrome, unexplained paresthesia, or progressive autonomic dysfunction should seek specialized neurological evaluation. Individuals with known genetic variants of the TTR gene or a family history of cardiomyopathy must avoid delaying diagnostic screenings. Invasive diagnostic procedures or specific targeted therapies are contraindicated in patients with severe, end-stage organ failure or active systemic infections without prior clinical stabilization by a multidisciplinary team.
